Larimar Therapeutics, INC 10-Q quarterly reports

Larimar Therapeutics reports progress on its nomlabofusp Biologics License Application submission and positive long-term safety data, while acknowledging substantial operating losses and the necessity for future capital raises.

Larimar Therapeutics reports Q1 2026 results, highlighting progress in nomlabofusp development for Friedreich's Ataxia and a strong cash position following recent financings.

Larimar Therapeutics, Inc. reported increased operating losses in Q3 2025 but highlighted positive clinical data for nomlabofusp in Friedreich's ataxia and plans for a Q2 2026 BLA submission.

Larimar Therapeutics reported increased net losses and cash burn in its second quarter, while making significant clinical and regulatory progress for its lead Friedreich's ataxia drug candidate, nomlabofusp.

Larimar Therapeutics' Q1 2025 report highlights ongoing clinical trials for nomlabofusp in Friedreich's ataxia, including positive FDA feedback and plans for a Phase 3 study, alongside increased R&D spending and a net loss of $29.3 million.

Larimar Therapeutics reported its third quarter 2024 financial results, highlighting progress in its nomlabofusp clinical program and ongoing open label extension study.

Larimar Therapeutics announced positive clinical trial results for its Friedreich's ataxia treatment, nomlabofusp, and provided a financial update for the second quarter of 2024.

Larimar Therapeutics announced positive top-line results from its Phase 2 dose exploration study of nomlabofusp and provided a financial update, including a recent capital raise.